How are ApoB and longevity related?

Apolipoprotein B (ApoB) is the primary protein in atherogenic lipoproteins (LDL, VLDL, IDL) and a key driver of atherosclerosis. Strong evidence from Mendelian randomization studies and long-term cohorts shows a causal relationship between elevated ApoB and cardiovascular events, which reduce life expectancy. Lowering ApoB—via statins, PCSK9 inhibitors, or lifestyle—reduces cardiovascular risk and can extend healthspan. However, longevity is multifactorial; ApoB is one piece of the puzzle. The evidence is human-strong, supported by RCTs and genetic data. Caveats: ApoB levels vary by ancestry and metabolic state; DTC tests may overstate individual impact. A comprehensive risk assessment (including Lp(a), inflammation) is recommended. MyBody-X can measure ApoB, but clinical interpretation is essential.